Jitter measurement with concentric needle in 133 patients with myasthenia gravis: a retrospective analysis

2017 ◽  
Author(s):  
Nermin Görkem Şirin ◽  
Elif Kocasoy Orhan ◽  
Hacer Durmuş ◽  
Piraye Oflazer ◽  
Yesim Parman ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Retrospective Analysis ◽  
Jitter Measurement

scholarly journals Myasthenia gravis with thymic epithelial tumour: a retrospective analysis of a Japanese database

2015 ◽  
Vol 49 (5) ◽  
pp. 1510-1515 ◽  
Author(s):  
Jun Nakajima ◽  
Meinoshin Okumura ◽  
Motoki Yano ◽  
Hiroshi Date ◽  
Takuya Onuki ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Retrospective Analysis ◽  
Epithelial Tumour

scholarly journals Methotrexate Use in Generalized Autoimmune Myasthenia Gravis: A Case series

2021 ◽  
Vol 2 (5) ◽  
Author(s):  
Preston Eibling ◽  
Yuebing Li ◽  
Robert Marquardt
Keyword(s):  
Side Effects ◽  
Myasthenia Gravis ◽  
Retrospective Analysis ◽  
Acetylcholine Receptor ◽  
Average Duration ◽  
Case Series ◽  
Immunosuppressive Medication ◽  
Autoimmune Myasthenia ◽  
Sparing Effect ◽  
Steroid Sparing

Methotrexate (MTX) is an inexpensive and well-tolerated immunosuppressive medication that is used anecdotally in autoimmune myasthenia gravis (MG). However, the efficacy in MG is unclear at this time. This retrospective analysis describes six patients with acetylcholine receptor antibody positive MG who were treated with MTX and corticosteroids. The efficacy of MTX was measured by steroid-sparing effect and the Myasthenia Gravis Foundation of America (MGFA) classification. MTX initiation was associated with a reduction in prednisone dosage in all patients. Minimal manifestation status was reached at an average duration of 10 months in 5 patients.  No patients were hospitalized for myasthenia gravis exacerbations. There were no major side effects experienced with MTX use.  This retrospective analysis suggests that MTX is safe and probably efficacious as a corticosteroid-sparing agent in the management of MG.

Retrospective Analysis of Safety and Outcomes of Rituximab for Myasthenia Gravis in Patients ≥ 65 Years Old

2021 ◽  
Author(s):  
Christopher T. Doughty ◽  
Joome Suh ◽  
William S. David ◽  
Anthony A. Amato ◽  
Amanda C. Guidon
Keyword(s):  
Myasthenia Gravis ◽  
Retrospective Analysis

Demographics of patients with myasthenia gravis in a tertiary hospital, Penang, Malaysia compared to world data – A retrospective analysis

2021 ◽  
Vol 429 ◽  
pp. 118403
Author(s):  
Eric Qiu Weng Hong ◽  
Tan Seng ◽  
Soong Loong ◽  
Mohd Hafidza Abdul Manaf ◽  
Muhammad Abidin ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Retrospective Analysis ◽  
Tertiary Hospital ◽  
World Data

Early and Late Results After Thymectomy in Myasthenia Gravis: a Retrospective Analysis

1999 ◽  
Vol 47 (03) ◽  
pp. 170-173 ◽  
Author(s):  
M. Klein ◽  
A. Granetzny ◽  
H.-P. Dauben ◽  
H. Schulte ◽  
E. Gams
Keyword(s):  
Myasthenia Gravis ◽  
Retrospective Analysis ◽  
Late Results ◽  
Early And Late Results

Prognosis of Ocular Myasthenia Gravis in an Argentinian Population

2018 ◽  
Vol 79 (3-4) ◽  
pp. 113-117 ◽  
Author(s):  
Florencia Aguirre ◽  
Andres M. Villa
Keyword(s):  
Myasthenia Gravis ◽  
Retrospective Analysis ◽  
Remission Rate ◽  
Acetylcholinesterase Inhibitors ◽  
Ocular Involvement ◽  
Achr Antibody ◽  
Ocular Myasthenia ◽  
Ocular Symptoms ◽  
Increased Risk ◽  
Ocular Myasthenia Gravis

Background: We investigated the prognosis of patients with myasthenia gravis (MG) initially presenting with only ocular symptoms in an Argentinian population. Summary: We performed a retrospective analysis of 61 patients with MG with pure ocular involvement at onset. Generalized MG (gMG) developed in 73.7% of patients, while the rest only exhibited ocular symptoms throughout the course of the disease (ocular MG [oMG]). The AChR antibody (AChR-ab) was found in 81.4% of the gMG and 50% of the oMG cases. AChR-ab titers were also significantly higher in the gMG than in the oMG group. Patients with oMG more frequently required treatment only with acetylcholinesterase inhibitors and showed more remissions. Key Messages: Our study showed high generalization in patients with MG debuting with ocular symptoms. Patients with AChR seropositivity and higher AChR-ab titers had an increased risk for gMG, while patients with oMG showed lower corticosteroid requirements and a higher remission rate.

Repetitive nerve stimulation and jitter measurement with disposable concentric needle electrode in newly diagnosed myasthenia gravis patients

2018 ◽  
Vol 48 (5) ◽  
pp. 261-267 ◽  
Author(s):  
Nermin Gorkem Sirin ◽  
Elif Kocasoy Orhan ◽  
Hacer Durmus ◽  
Feza Deymeer ◽  
Mehmet Baris Baslo
Keyword(s):  
Myasthenia Gravis ◽  
Nerve Stimulation ◽  
Needle Electrode ◽  
Newly Diagnosed ◽  
Repetitive Nerve Stimulation ◽  
Jitter Measurement

scholarly journals Treatment of myasthenia gravis patients with calcineurin inhibitors in Japan: A retrospective analysis of outcomes

2015 ◽  
Vol 6 (2) ◽  
pp. 195-200 ◽  
Author(s):  
Kimiaki Utsugisawa ◽  
Yuriko Nagane ◽  
Tomihiro Imai ◽  
Masakatsu Motomura ◽  
Masayuki Masuda ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Retrospective Analysis ◽  
Calcineurin Inhibitors

AB043. PS02.07: Features of thymoma-associated myasthenia gravis: a retrospective analysis on 346 patients

Mediastinum ◽  
2017 ◽  
Vol 1 ◽  
pp. AB043-AB043
Author(s):  
Anna De Rosa ◽  
Roberta Ricciardi ◽  
Michelangelo Maestri ◽  
Melania Guida ◽  
Antonio Chella ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Retrospective Analysis
Sign in / Sign up

Export Citation Format

Share Document